{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-062941","form_type":"8-K","ticker":"CLSDQ","cik":"0001539029","company_name":"Clearside Biomedical, Inc.","filed_at":"2023-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.461209+00:00","generated_at":"2026-06-08T05:05:51.334137+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Clearside Q3 net loss $9.3M; inks BioCryst licensing deal for DME with $5M upfront","bullets":["Net loss of $9.3M ($0.15/share) vs $7.8M loss ($0.13/share) in Q3 2022.","Cash $28.8M at Sep 30; +$5M upfront from BioCryst extends runway into Q4 2024.","Licensed avoralstat (plasma kallikrein inhibitor) to BioCryst for DME; up to $77.5M milestones plus royalties.","Completed recruitment in Phase 2b ODYSSEY wet AMD trial; topline data expected Q3 2024.","Arctic Vision finished Phase 3 UME trial enrollment in China; Bausch+Lomb granted new CPT code for XIPERE."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-062941","json":"https://secwatch.observer/filing/0000950170-23-062941.json","markdown":"https://secwatch.observer/filing/0000950170-23-062941.md","text":"https://secwatch.observer/filing/0000950170-23-062941.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1539029/000095017023062941/0000950170-23-062941-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1539029/000095017023062941/clsd-20231113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T05:05:51.334137+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"efae6d241390f4bb40dfa442a35b47023bbb128e","claim":"Clearside Biomedical, Inc. reported financial results for the quarter ended September 30, 2023.","evidence_excerpt":"On November 13, 2023, Clearside Biomedical, Inc. (the “ Registrant ”) issued a press release announcing its financial results for the quarter ended September 30, 2023, as well as information regarding a conference call to discuss these financial results and the Registrant’s recent corporate highlights.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1539029/000095017023062941/0000950170-23-062941-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}